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906Background: Several randomized clinical trials evaluated whether preoperative supplementation of omega-3
(n-3) polyunsaturated fatty acids protects against postoperative atrial fibrillation after cardiac surgery,
a condition associated with increased cardiac and cerebral mortality. However, their efficacy remains still
controversial. An updated meta-analysis was performed to clarify if preoperative n-3 polyunsaturated fatty
acid supplementation prevents postoperative atrial fibrillation in patients undergoing cardiac surgery.
Methods: Articles were retrieved until November 2012 by screening electronic databases (PubMed, EMBASE,
Web of Science, and Cochrane Central Register of Controlled Trials) and cross references. Two of us indepen-
dently reviewed articles and agreed to select 8 randomized clinical trials. For each study, the incidence of atrial
fibrillation in both the intervention and placebo groups was extracted to calculate odd ratio and 95% confidence
intervals (CIs). Weighted study-specific estimates were combined using fixed (Mantel-Haenszel method) and
random-effects (DerSimonian-Laird method) models.
Results: This meta-analysis includes 2687 patients (1337 in the intervention group) who underwent cardiac sur-
gery. Pooled analysis using fixed-effects models showed a significant reduction (average, 16%; 95% CI,
1%-29%) in postoperative atrial fibrillation by preoperative n-3 polyunsaturated fatty acids. There was a low
heterogeneity among studies (P¼ .07 and I2¼ 46%). By using a random-effects model, the reduction averaged
25% (odds ratio, 0.75; 95% CI, 0.57-1.00; P ¼ .05). When isolated coronary artery bypass graft surgery was
only considered (7 studies), a significant protection averaging 34% was observed in a fixed model (odds ratio,
0.66; 95% CI, 0.50-0.87; P ¼ .003; I2 ¼ 26%, P ¼ .23).
Conclusions: A preoperative supplementation of n-3 polyunsaturated fatty acids significantly prevents the oc-
currence of postoperative atrial fibrillation in patients undergoing cardiac surgery, in particular coronary artery
bypass surgery. (J Thorac Cardiovasc Surg 2013;146:906-11)Atrial fibrillation (AF) is the most common type of
arrhythmia after cardiac surgery. The incidence of
postoperative atrial fibrillation (POAF) ranges from 20%
to 50% and depends on patient age, predisposing and intra-
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The POAF is associated with prolonged hospitalization
(intensive care unit and hospital stays), increased total
hospital costs, morbidity, and all-cause mortality.3-5
In addition to the traditional antiarrhythmic therapy, new
and upstream (nonantiarrhythmic) therapies received in-
creasing attention for preventing POAF.6,7 Among the
latter therapies, omega-3 (n-3) polyunsaturated fatty acids
(PUFAs), with their anti-inflammatory properties and anti-
arrhythmic effects, may be a valid candidate to reduce
POAF incidence after open heart surgery.6
Recent meta-analyses8-10 and systematic reviews6,11
have evaluated whether preoperative supplementation of
n-3 PUFA protects against POAF in patients undergoing
cardiac surgery, but more recent studies have reported less
conclusive data, so that there are still doubts about their
real efficacy.
This updated meta-analysis of prospective randomized
clinical trials was performed to better clarify if preoperative
n-3 PUFA supplementation would prevent POAF after car-
diac surgery. In addition, focus was paid to the effect of n-3ery c October 2013
Abbreviations and Acronyms
AF ¼ atrial fibrillation
CABG ¼ coronary artery bypass graft
CI ¼ confidence interval
n-3 ¼ omega-3
OHS ¼ open heart surgery
OR ¼ odds ratio
POAF ¼ postoperative atrial fibrillation
PUFA ¼ polyunsaturated fatty acid
RCT ¼ randomized controlled trial
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MPUFA on POAF after a specific type of surgery (ie, isolated
coronary artery bypass graft [CABG] surgery).
METHODS
Search Strategy
Articles were retrieved until November 2012 by searching in PubMed,
EMBASE, Web of Science, and Cochrane Central Register of Controlled
Trials, using the following key words: omega 3 fatty acids, eicosapentae-
noic acid, docosahexaenoic acid, fish oils, atrial fibrillation, cardiac
surgery, cardiopulmonary bypass, open heart surgery, cardiac valve sur-
gery, and coronary artery bypass graft, supplemented by references from
the selected articles and by abstracts from congress proceedings, to mini-
mize the publication bias. After a preliminary literature search, 156 publi-
cations were identified and, of these publications, by screening titles and
text abstracts, 28 potentially relevant articles were selected (Figure 1).
The inclusion criteria were as follows: (1) the study design was a pro-
spective randomized control trial, (2) the study population included pa-
tients undergoing an open heart surgery, (3) it was possible to extract
quantitative data, and (4) POAFwas defined as an episode of AF that lasted
longer than 5 minutes and/or was clinically recognized. Taking into
account these inclusion criteria, two of us (S.C. and V.d.N.) first indepen-
dently reviewed and scored the 28 identified studies, then jointly excluded
the articles irrelevant to the current analysis (Figure 1) and agreed on the
final selection of 8 randomized clinical trials12-19 on efficacy of n-3
PUFA for the prevention of AF after open heart surgery.
Quality Assessment
The same 2 reviewers (S.C. and V.d.N.) independently assessed the
methodological quality of included studies using the Jadad scale.20 Dis-
agreementswere resolved by discussion or involving a third reviewer (F.G.).
Data Extraction and Data Analysis
For each of the selected studies, the incidence of POAF in both the in-
tervention and control groups was extracted to calculate the odd ratio (OR)
and 95% confidence intervals (CIs). For the study of Saravanan et al,14 in
which the authors used 2 definitions of POAF (AF 30 seconds in the life
card monitor recording and clinically recognized AF), we only selected
data concerning clinically recognized AF, as used in all other randomized
controlled trials (RCTs). Moreover, we obtained the incidence of POAF
separately for type of cardiac surgery (CABG or valve replacement/repair)
and type of CABG technique (on-pump/off-pump CABG) by directly con-
tacting the authors of 4 RCTs.12,15,16,18 All analyses were performed using
standard statistical procedures provided in RevMan5.1 (The Cochrane
Collaboration, Oxford, United Kingdom). Weighted study-specific esti-
mates were combined using fixed (Mantel-Haenszel method) and random
(DerSimonian-Laird method) effects models. If statistically significant het-
erogeneity between studies was not identified, the fixed-effect estimate was
preferentially used as a summary measure. The hypothesis that publicationThe Journal of Thoracic and Cabias might have affected the validity of the estimates was tested by a funnel
plot–based approach. A simple test of asymmetry of the funnel plot was
used according to the method proposed by Egger et al.21
RESULTS
The baseline characteristics of the selected studies are
shown in Table 1. Four studies12-14,17 included patients
undergoing isolated CABG surgery, 1 included CABG with
or without concomitant valve surgery,18 and 3 included
CABG, cardiac valve surgery, or combinedprocedures15,16,19
(Table 1).
n-3 PUFA and Prevention of POAF in Open Heart
Surgery
This meta-analysis includes 2687 patients (1337 in the
n-3 PUFA–treated patients) who underwent open heart sur-
gery. No evidence of publication bias was found using the
Egger test (P ¼ .2). By using fixed-effects models, pooled
analysis showed a significant reduction in POAF by preop-
erative n-3 PUFA supplementation (OR, 0.84; 95% CI,
0.71-0.99; P ¼ .04) (Figure 2 and Table 2). There was
a low heterogeneity among studies (P ¼ .07 and
I2 ¼ 46%). By using a random-effects model, the result
was as follows: OR, 0.75; 95% CI, 0.57-1.00; P ¼ .050.
Sensitivity and subgroup analyses were performed to
investigate the source of heterogeneity among studies.
n-3 PUFA and Prevention of POAFAccording to
Type of Surgery
Data on patients who underwent isolated CABG surgery
were extracted from 7 studies12-18 (1028 patients, Figure 2).
For the studies of Heidarsdottir,15 Farquharson,16 and San-
desara,18 data on isolated CABG were obtained from the
authors (Figure 3 and Table 2). No evidence of publication
bias was found (P ¼ .92). Significant protection was ob-
served in both a fixed-effects model (OR, 0.66; 95% CI,
0.50-0.87;P¼ .003; I2¼ 26%,P¼ .23) (Figure 3) and a ran-
dom-effects model (OR, 0.66; 95% CI, 0.47-0.92; P¼ .01).
The effect of PUFA supplementation was also investi-
gated in a subgroup of studies on open heart surgeries
(OHSs) (Table 2). In this sensitivity analysis, in which 3
studies15,16,19 considered indiscriminately patients who
underwent CABG, cardiac valve surgery, or combined
procedures (Table 1), the effect of PUFA was as follows:
OR, 0.92 (95% CI, 0.76-1.12; P ¼ .40; I2 ¼ 0%,
P¼ .38). Moreover, data on patients who underwent a valve
surgery or CABG combined with other cardiac surgery
were extracted from 3 studies15,16,18; however, their
pooled analysis showed a high heterogeneity among
studies and the few patients (64 n-3 PUFA-treated patients
and 79 controls) limited the statistical power (Table 2).
Interestingly, the heterogeneity was clearly reduced
within isolated CABG (I2 ¼ 26%) and OHS (I2 ¼ 0%)
subgroups, indicating that a consistent part of the overallrdiovascular Surgery c Volume 146, Number 4 907
FIGURE 1. Flow chart of the selected studies. POAF, Postoperative atrial
fibrillation.
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Mheterogeneity originated from the difference in the type of
surgery (I2 ¼ 46%, P ¼ .07). In addition, we performed
TABLE 1. Characteristics of RCTs included in the meta-analysis
Study Country
Type of
study Surgery
Total
no. of
patients JQS
St
a
Calo et al,12 2005 Italy R, OL CABG 160 3 Con
Trea
Heidt et al,13 2009 Germany R, DB CABG 102 4 Con
Trea
Saravanan et al,14
2009
United
Kingdom
R, DB CABG 103 5 Con
Trea
Heidarsdottir et al,15
2010
Iceland R, DB OHS 168 4 Con
Trea
Farquharson et al,16
2011
Australia R, DB OHS 194 5 Con
Trea
Sorice et al,17 2011 Italy R CABG 201 3 Con
Trea
Sandesara et al,18
2012
United
States
R, DB CABGy 243 4 Con
Trea
Mozaffarian et al,19
2012
Argentina,
Italy,
United
States
R, DB OHS 1516 5 Con
Trea
RCT, Randomized controlled trial; JQS, JADAD quality score; POAF, postoperative atri
n-3 PUFA, omega-3 polyunsaturated fatty acids; EPA, eicosapentaenoic acid; DHA, doco
SD, standard deviation. *Median (25th and 75th percentiles) of age. yIsolated CABG or c
908 The Journal of Thoracic and Cardiovascular Surga sensitivity analysis in 5 studies,12-14,16,17 only considering
on-pump isolated CABG (294 n-3 PUFA-treated patients of
a total of 575 patients), by using a random model (OR,
0.57; 95% CI, 0.32-1.01; P ¼ .05; I2 ¼ 54%, P ¼ .07)
(Table 2).n-3 PUFA and Prevention of POAFAccording to
Type of Placebo
Table 1 also reports the type of placebo used in each
selected study: usual care,12,17 olive,14,15,19 soya,13 sun-
flower,16 or corn18 oils. There was no apparent beneficial ef-
fect of n-3 PUFAwhen the olive oil was used as a placebo
compared with the other 2 subgroups (usual care and other
vegetable oils), although P for difference was equal to .13
among subgroups (Table 2).udy
rm
No. of
patients
Age,
mean ± SD
Men,
No. (%) Intervention
POAF
rate,
No. (%)
trol 81 64.9  9.1 68 (84) Usual care 27 (33.3)
tment 79 66.2  8.0 68 (86) n-3 PUFA: 2 g/d
(EPA:DHA,
1:2)
12 (15.2)
trol 50 68.1  9.7 32 (64) Soya oil: 100
mg/kg per day
15 (30.0)
tment 52 64.7  12.8 38 (73) Fish oil: 100
mg/kg per day
(EPA:DHA,
0.9:1)
9 (17.3)
trol 51 68 (64-73) 42 (82) Olive oil: 2 g/d 18 (35.3)
tment 52 64 (58-71)* 40 (77) n-3 PUFA: 2 g/d
(EPA:DHA,
1.2:1)
22 (42.3)
trol 85 67 (43-82) 65 (77) Olive oil: 2 g/d 46 (54.1)
tment 83 67 (45-82)* 68 (82) 1.24 g/d EPA;
1 g/d DHA
45 (54.2)
trol 97 64.0  10.0 62 (64) Sunflower oil:
15 mL/d
47 (48.4)
tment 97 64.0  11.0 80 (82) Fish oil: 15 mL/d
(EPA:DHA,
1.42:1)
36 (37.1)
trol 105 63.0  9.0 88 (84) NR (usual care) 24 (22.9)
tment 96 64.0  10.0 76 (79) n-3 PUFA: 2 g/d
(EPA:DHA,
1:2)
11 (11.4)
trol 123 62.0  11.4 102 (83) Corn oil: 2 g/d 40 (32.5)
tment 120 63.4  9.5 94 (78) n-3 PUFA: 4 g/d
(EPA:DHA,
1.24:1)
36 (30.0)
trol 758 63.6  12.4 543 (72) Olive oil: NR 233 (30.7)
tment 758 63.8  12.6 551 (73) n-3 PUFA: 2-4
g/d (EPA:DHA,
1.24:1)
227 (30.0)
al fibrillation; R, randomized; OL, open label; CABG, coronary artery bypass graft;
sahexaenoic acid; DB, double blinding; OHS, open heart surgery; NR, not reported;
ombined with cardiac valve surgery.
ery c October 2013
FIGURE 2. Omega-3 polyunsaturated fatty acids (n-3 PUFA) and prevention of postoperative atrial fibrillation in open heart surgery. M-H, Mantel-
Haenszel; CI, confidence interval.
Costanzo et al Perioperative ManagementA sensitivity analysis on methodological quality of stud-
ies has not been performed, because no study was of a low
quality (Jadad score  2, Table 1).
DISCUSSION
The present meta-analysis on the effect of preoperative
n-3 PUFA supplementation in POAF prevention after car-
diac surgery was undertaken to overcome some remarkable
limitations of previous ones, such as the availability of few
studies only, their small sample size,8-10,22,23 and several
sources of heterogeneity, such as the type of surgery and/
or of placebo. Consequently, the results of previous meta-
analyses had low statistical power and rather inconclusive
findings.
The current meta-analysis was based on 2687 (n-3 PUFA
treated, 1337) patients from 8 studies and included 2 recent
randomized clinical trials,18,19 1 of which had enrolled
a consistent number of patients.19 Preoperative n-3 PUFA
supplementation significantly reduced by an average of
16% the odds of POAF after open heart surgery (Figure 2),
a result in line with a previous smaller meta-analysis.9 TheTABLE 2. Sensitivity analyses according to type of surgery and placebo
Subgroup
No. of
studies
n-3 PUFA Contro
POAF
events Total
POAF
events T
All studies 8 398 1337 450 1
Type of surgeries
OHS 3 308 938 326
Isolated CABG 7 132 515 172
On-pump isolated CABG 5 70 294 95
Valve surgery or CABG combined
with other cardiac surgeries
3 39 64 45
Type of placebo
Usual care 2 23 175 51
Olive oil 3 294 893 279
Other vegetal oils 3 81 269 102
n-3 PUFA, Omega-3 polyunsaturated fatty acids; POAF, postoperative atrial fibrillation; O
heart surgery; CABG, coronary artery bypass graft.
The Journal of Thoracic and Caobserved reduction was more than double (average, 34%;
being basal incidence of POAF, 33.5%) when only patients
undergoing isolated CABG were considered. The latter find-
ing, which was obtained by pooling all studies but the largest
one, which did not include patients with CABG,19 represents
the main novelty of the present meta-analysis (Figure 3 and
Table 2).
The pathophysiological characteristics of POAF after
open heart surgery are multifactorial, but not well known
yet. Several factors are considered to be associated with
the development of POAF: predisposing factors, such as ad-
vanced age, hypertension, diabetes, obesity, and metabolic
syndrome; intraoperative factors, such as surgical injury,
atrial ischemia, pulmonary vein vent, venous cannula, and
acute volume changes; and postoperative factors, such as
volume overload, increased afterload, and hypotension.
The main common pathways of all these factors are inflam-
mation and oxidative stress.1,24,25
Current guidelines recommend the use of antiarrhythmic
drugs to decrease the risk ofPOAFafter cardiac surgery.How-
ever, the patient is not fully protected from POAF by usingl
OR (95% CI)
P
value Model I2 value,%
P value for
heterogeneityotal
350 0.84 (0.71-0.99) .04 FE 46 .07
0.75 (0.57-1.00) .05 RE
758 0.92 (0.76-1.12) .4 FE 0 .38
513 0.66 (0.50-0.87) .003 FE 26 .23
281 0.59 (0.41-0.85) .005 FE 54 .07
0.57 (0.32-1.01) .05 RE
79 1.15 (0.59-2.24) .67 FE 69 .04
1.48 (0.39-5.54) .56 RE
186 0.40 (0.23-0.68) .0009 FE 0 .72
894 0.99 (0.81-1.21) .91 FE 0 .73
270 0.71 (0.49-1.01) .06 FE 0 .49
R, odds ratio; CI, confidence interval; FE, fixed effect; RE, random effect; OHS, open
rdiovascular Surgery c Volume 146, Number 4 909
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FIGURE 3. Omega-3 polyunsaturated fatty acids (n-3 PUFA) and prevention of postoperative atrial fibrillation in isolated coronary artery bypass graft
surgery. M-H, Mantel-Haenszel; CI, confidence interval.
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Monly these agents; thus, newer therapies (nonantiarrhythmic
drugs) for the management of atrial fibrillation are needed to
be used in combination with them.1,6 Recently, the efficacy
of several agents (drugs or nutraceuticals) in preventing
POAF have been investigated. Among nonantiarrhythmic
drugs, preoperative colchicine use (Colchicine for the
Prevention of the Postpericardiotomy Syndrome substudy)26
showed a reduction of relative risk of 45% in POAF occur-
rence, corticosteroids were associated with a reduction of
relative risk of 26% to 58%,6 and a recent systematic review
concluded that preoperative statin therapy is also effective.27
Focusing on nutraceutical agents, n-3 PUFAs have been
studied more frequently than others: the beneficial effect
of a preoperative supplementation of n-3 PUFA on POAF
is likely explained by the documented anti-inflammatory
activity of PUFA.28-31 Experimental studies have also
suggested a direct potential antiarrhythmic effect of n-3
PUFA.6,28,32 However, a diet rich in fish oil might have
both proarrhythmic and antiarrhythmic proprieties,
depending on the background of arrhythmia mechanisms
and their vulnerable parameters.33,34
During CABG, and other OHSs, a stronger and persistent
stimulation of inflammation is likely to occur, due to both
the nature of the disease35 and the influence of the operation
techniques.36 Regarding our findings, the beneficial effect
of fish oil supplementation in reducing POAF could be
more easily detectable in patients undergoing CABG com-
pared with conditions characterized by a lower-grade
inflammatory reaction.
Interestingly, sensitivity analysis suggests that the efficacy
of n-3PUFAsupplementationwouldvary in relation to thepla-
cebo used in the trial. Indeed, its efficacywas somewhat higher
when comparedwith usual care, rather thanwith olive or other
oils, a nonsignificant difference, however. One possible expla-
nation is that corn, sunflower, and olive oil supplementation,
because of their antioxidant content, could be associated
with increased long-chain n-3 PUFA levels in plasma and
redblood cellmembranes, independently of fishoil intake.37,38
There are, however, some limitations of our meta-
analysis owing to the relatively few and the heterogeneity
of selected RCTs and the unfeasibility to perform910 The Journal of Thoracic and Cardiovascular Surgsensitivity analysis for different dietary habits (eg, low or
high fish intake), antiarrhythmic or other cardiovascular
drug use, or other preoperative variables. Eussen et al39 sug-
gested that statin treatment modifies the effects of n-3 PUFA
on the incidence of major cardiovascular events; as in statin
users, n-3 PUFA supplementation had no additive effect on
major cardiovascular events. In addition to their effects on
blood lipids, statins reportedly share with n-3 PUFA some
anti-inflammatory effects, improve endothelial function,
and inhibit platelet aggregation.40 Furthermore, differences
in PUFA formulations and dosage and in the duration of
supplementation among the studies did not allow the estab-
lishment of the optimal dose(s) of PUFAs endowed with
their anti-arrhythmic effect. The trial with the largest sam-
ple size,19 contributing half of the total weight of the studies
included in our meta-analysis, failed to show any significant
effect of PUFA (OR, 0.96; 95% CI, 0.77-1.20). However,
this trial included many open heart surgeries (cardiac valve
surgery or combined procedures) and used olive oil as a pla-
cebo. Moreover, this was also the most recent study and
many patients might have benefited from state-of-the-art
treatments, making any added benefit from the omega 3
supplementation more difficult to detect.41
A major problem this meta-analysis shares with other
similar statistical approaches remains that of the weight
to be given to several smaller clinical trials, resulting in
a pooled beneficial effect of n-3 PUFA in respect to a sin-
gle larger trial reporting no significant benefits. In addi-
tion, our meta-analysis is limited by the heterogeneity
of the studies (type of surgery or placebo) and the lack
of availability of additional data on preoperative charac-
teristics of enrolled patients. In the future, the effect on
POAF of preoperative supplementation of n-3 PUFA
should better be studied in a well-characterized patient
population undergoing a single type of cardiac surgery
procedure.
In conclusion, keeping in mind the limitations previously
mentioned, a preoperative supplementation of n-3 PUFA to
patients undergoing isolated CABG surgery significantly
prevents the occurrence of POAF after an isolated CABG
surgery.ery c October 2013
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